ACOG practice bulletin no. 84: Prevention of deep vein thrombosis and pulmonary embolism

Obstetrics and Gynecology

Volumn 110, Issue 2 I, 2007, Pages 429-440

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; ANTIVITAMIN K; CLOPIDOGREL; CONTRACEPTIVE AGENT; DALTEPARIN; ENOXAPARIN; ESTROGEN; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLUCOSAMINE; GREEN TEA EXTRACT; HEPARIN; HYPERICUM PERFORATUM EXTRACT; IBUPROFEN; LOW MOLECULAR WEIGHT HEPARIN; MELATONIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; SALVIA MILTIORRHIZA EXTRACT; THROMBOCYTE SLOWING FACTOR; TICLOPIDINE; TRIGONELLA FOENUM GRAECUM EXTRACT; UBIDECARENONE; UNINDEXED DRUG; WARFARIN;

ANESTHESIA; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRANBERRY JUICE; DEATH; DEEP VEIN THROMBOSIS; DEVICE; DISABILITY; EVIDENCE BASED MEDICINE; FENUGREEK; FOOD DRUG INTERACTION; GYNECOLOGIC SURGERY; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL DECISION MAKING; MEDICAL LITERATURE; POSTOPERATIVE PERIOD; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROPHYLAXIS; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; VEIN INSUFFICIENCY; VENOUS THROMBOEMBOLISM;

EID: 34548462992     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000263919.23437.15     Document Type: Review

References (75)

1. Hoyert DL, Heron MP, Murphy SL, Kung HC. Deaths: final data for 2003. Natl Vital Stat Rep 2006;54:1-120. (Level II-3)
2. Rubinstein I, Murray D, Hoffstein V. Fatal pulmonary emboli in hospitalized patients. An autopsy study. Arch Intern Med 1988;148:1425-6. (Level III)
3. Kaunitz AM, Hughes JM, Grimes DA, Smith JC, Rochat RW, Kafrissen ME. Causes of maternal mortality in the United States. Obstet Gynecol 1985;65:605-12. (Level II-3)
4. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl): 338S-400S. (Level III)
5. Ibrahim EH, Iregui M, Prentice D, Sherman G, Kollef MH, Shannon W. Deep vein thrombosis during prolonged mechanical ventilation despite prophylaxis. Crit Care Med 2002;30:771-4. (Level II-3)
6. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996;93:2212-45. (Level III)
7. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60. (Level II-3)
8. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004;117:19-25. (Level I)
9. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8. (Level III)
10. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-5. (Level II-2)
11. Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95. (Level II-3)
12. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl):132S-75S. (Level III)
13. Clarke-Pearson DL, Dodge RK, Synan I, McClelland RC, Maxwell GL. Venous thromboembolism prophylaxis: patients at high risk to fail intermittent pneumatic compression. Obstet Gynecol 2003;101:157-63. (Level II-2)
14. Clarke-Pearson DL, Synan IS, Dodge R, Soper JT, Berchuck A, Coleman RE. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146-53; discussion 1153-4. (Level I)
15. Maxwell GL, Synan I, Dodge R, Carroll B, Clarke-Pearson DL. Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. Obstet Gynecol 2001;98:989-95. (Level I)
16. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-5. (Level I)
17. Wille-Jorgensen P, Rasmussen MS, Andersen BR, Borly L. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD001217. DOI: 10.1002/14651858.CD001217. (Level III)
18. Middeldorp S, Henkens CM, Koopman MM, van Pampus EC, Hamulyak K, van der Meer J, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20. (Level II-3)
19. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993;90:1004-8. (Level III)
20. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4. (Level II-3)
21. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8. (Level II-2)
22. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703. (Level II-2)
23. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005;1-12. (Level III)
24. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-8. (Level II-2)
25. Oger E, Lacut K, Le Gal G, Couturaud F, Guenet D, Abalain JH, et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. EDITH Collaborative Study Group. J Thromb Haemost 2006;4:793-9. (Level II-2)
26. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005;3:1646-54. (Level III)
27. de Groot PG, Derksen RH. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis 2005;18:205-10. (Level III)
28. Bertolaccini ML, Khamashta MA, Hughes GR. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 2005;1:40-6. (Level III)
29. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001484. DOI: 10.1002/14651858.CD001484. (Level III)
30. Byrne B. Deep vein thrombosis prophylaxis: the effectiveness and implications of using below-knee or thigh-length graduated compression stockings. Heart Lung 2001;30:277-84. (Level III)
31. Agu O, Hamilton G, Baker D. Graduated compression stockings in the prevention of venous thromboembolism. Br J Surg 1999;86:992-1004. (Level III)
32. Ginzburg E, Cohn SM, Lopez J, Jackowski J, Brown M, Hameed SM. Randomized clinical trial of intermittent pneumatic compression and low molecular weight heparin in trauma. Miami Deep Vein Thrombosis Study Group. Br J Surg 2003;90:1338-44. (Level I)
33. Kohro S, Yamakage M, Sato K, Sato JI, Namiki A. Intermittent pneumatic foot compression can activate blood fibrinolysis without changes in blood coagulability and platelet activation. Acta Anaesthesiol Scand 2005;49:660-4. (Level II-3)
34. Tarnay TJ, Rohr PR, Davidson AG, Stevenson MM, Byars EF, Hopkins GR. Pneumatic calf compression, fibrinolysis, and the prevention of deep venous thrombosis. Surgery 1980;88:489-96. (Level II-1)
35. Killewich LA, Cahan MA, Hanna DJ, Murakami M, Uchida T, Wiley LA, et al. The effect of external pneumatic compression on regional fibrinolysis in a prospective randomized trial. J Vasc Surg 2002;36:953-8. (Level I)
36. Cahan MA, Hanna DJ, Wiley LA, Cox DK, Killewich LA. External pneumatic compression and fibrinolysis in abdominal surgery. J Vasc Surg 2000;32:537-43. (Level I)
37. Clarke-Pearson DL, Synan IS, Hinshaw WM, Coleman RE, Creasman WT. Prevention of postoperative venous thromboembolism by external pneumatic calf compres sion in patients with gynecologic malignancy. Obstet Gynecol 1984;63:92-8. (Level I)
38. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-40. (Meta-analysis)
39. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-73. (Level III)
40. Clarke-Pearson DL, Coleman RE, Synan IS, Hinshaw W, Creasman WT. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol 1983;145:606-13. (Level I)
41. Clarke-Pearson DL, DeLong E, Synan IS, Soper JT, Creasman WT, Coleman RE. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol 1990;75:684-9. (Level I)
42. Clarke-Pearson DL, DeLong ER, Synan IS, Creasman WT. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol 1984;64:689-94. (Level II-1)
43. Holzheimer RG. Prophylaxis of thrombosis with low-molecular-weight heparin (LMWH). Eur J Med Res 2004;9:150-70. (Level III)
44. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published erratum appears in: Chest 2005;127:416]. Chest 2004;126(suppl):311S-37S. (Level III)
45. Kakkar VV, Murray WJ. Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: a co-operative study. Br J Surg 1985;72:786-91. (Level I)
46. Cyrkowicz A. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis. Eur J Obstet Gynecol Reprod Biol 2002;100:223-6. (Level II-2)
47. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. ENOXACAN II Investigators. N Engl J Med 2002;346:975-80. (Level I)
48. Roderick P, Ferris G, Wilson K, Halls H, Jackson D, Collins R, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess 2005 Dec;9:iii-iv, ix-x, 1-78. (Level III)
49. Food and Drug Administration (US). Subject: Reports of epidural or spinal hematomas with the concurrent use of low molecular weight heparin and spinal/epidural anesthesia or spinal puncture. FDA Public Health Advisory. Rockville (MD): FDA; 1997. Available at: http://www.fda.gov/medwatch/safety/ 1997/antico.htm. Retrieved April 26, 2007. (Level III)
50. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969;2:230-2. (Level II-3)
51. Clarke-Pearson DL, Synan IS, Colemen RE, Hinshaw W, Creasman WT. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol 1984;148:1051-4. (Level II-3)
52. Haas S, Flosbach CW. Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. Semin Thromb Hemost 1993;19(suppl 1):164-73. (Level I)
53. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 2003;124(suppl):379S-85S. (Level III)
54. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. Women's Health Initiative Investigators. JAMA 2004;292:1573-80. (Level I)
55. Curb JD, Prentice RL, Bray PF, Langer RD, Van Horn L, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80. (Level I)
56. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986;292:526. (Level II-2)
57. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002;65:187-96. (Level II-2)
58. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22:201-10. (Level III)
59. Robinson GE, Burren T, Mackie IJ, Bounds W, Walshe K, Faint R, et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. BMJ 1991;302:269-71. (Level III)
60. Bonnar J. Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? Am J Obstet Gynecol 1999;180:784-91. (Level III)
61. Florell SR, Rodgers GM. Inherited thrombotic disorders: an update. Am J Hematol 1997;54:53-60. (Level III)
62. Bokarewa MI, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92:473-8. (Level II-3)
63. Dahlback B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217-34. (Level III)
64. Dizon-Townson DS, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997;176:883-6. (Level III)
65. Faioni EM, Razzari C, Martinelli I, Panzeri D, Franchi F, Mannucci PM. Resistance to activated protein C in unselected patients with arterial and venous thrombosis. Am J Hematol 1997;55:59-64. (Level II-2)
66. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3. (Level II-2)
67. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996;93:487-90. (Level III)
68. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7. (Level II-2)
69. Simioni P, Prandoni P, Lensing AW, Manfrin D, Tormene D, Gavasso S, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deepvein thrombosis. Blood 2000;96:3329-33. (Level II-2)
70. Maxwell GL, Myers ER, Clarke-Pearson DL. Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. Obstet Gynecol 2000;95:206-14. (Level III)
71. Dainty L, Maxwell GL, Clarke-Pearson DL, Myers ER. Cost-effectiveness of combination thromboembolism prophylaxis in gynecologic oncology surgery. Gynecol Oncol 2004;93:366-73. (Level III)
72. Kennedy J. Herb and supplement use in the US adult population. Clin Ther 2005;27:1847-58. (Level II-3)
73. Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost 2005;93:3-7. (Level III)
74. Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003;55:112-3. (Level III)
75. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herb-drug interactions: a literature review. Drugs 2005;65:1239-82. (Level III)